In a completed phase I study of sotrastaurin, a potent, selective oral inhibitor of both the classical and novel isoforms of PKC, 153 patients with metastatic uveal melanoma received total daily doses of sotrastaurin ranging from 450 to 1400 mg on a twice daily or three times daily dosing schedule [12]. The gene discussed is PRRT2; the disease is uveal melanoma.